Poly Medicure , a prominent player in the medical devices sector, has made headlines with a significant block trade and an announcement of an upcoming investor meeting.

Block Trade Details

The company recently completed a substantial block trade on the National Stock Exchange (NSE). The transaction involved approximately 116,048 shares changing hands at a price of Rs. 2,004.90 per share, amounting to a total value of Rs. 23.27 crores.

Upcoming Investor Meeting

In a separate development, Poly Medicure has informed the stock exchanges about an upcoming investor meeting. According to the company's regulatory filing:

• Date: Thursday, 11th September, 2025
• Participant: PineBridge Investments
• Venue: Physical meeting at the Company's Registered Office

The company emphasized that no Unpublished Price Sensitive Information will be shared during the meeting, adhering to regulatory compliance.

Management's Statement

Avinash Chandra, Company Secretary of Poly Medicure, stated in the filing, "The above schedule is subject to changes which may happen due to exigencies on the part of the Analysts/Investors/the Company."

About Poly Medicure Ltd.

Poly Medicure Limited is a leading medical device manufacturer with a global presence. The company operates manufacturing facilities in Faridabad, Haryana, and has been expanding its product portfolio in recent years.

Investor Considerations

While the block trade indicates significant investor interest in Poly Medicure, potential investors should note that past performance does not guarantee future results. As always, it is advisable to conduct thorough research and consider one's financial goals before making investment decisions.

The upcoming investor meeting may provide further insights into the company's strategies and outlook, which could be of interest to current and prospective shareholders alike.

Poly Medicure , a leading medical device manufacturer, has announced the acquisition of a 90% stake in PendraCare Group, a Netherlands-based interventional cardiology company, for EUR 14.2 million. This strategic move is set to bolster Poly Medicure's global presence in the cardiology sector and expand its product portfolio.

Transaction Details

The acquisition includes:

• An upfront equity consideration of EUR 11.00 million
• Assumption of EUR 3.20 million in inter-group loan liabilities
• Taking over EUR 2.90 million in net debt

The deal values PendraCare at:

• 1.8x EV/revenue
• 13x EV/EBITDA (based on PendraCare's 2024 financial performance)

PendraCare Group Overview

PendraCare Group, headquartered in Leek, Netherlands, is a well-established player in the interventional cardiology space. Key highlights include:

• Specialization in guiding and diagnostic catheters
• Serving over 35 countries through more than 50 distributor relationships
• 2024 financial performance:
  • Revenue: EUR 9.90 million
  • EBITDA: EUR 1.40 million
  • Gross margins: 74%

Strategic Rationale

Rahul Gautam, President of Corporate Strategy & Development at Poly Medicure, highlighted the strategic importance of the acquisition:

1. Expansion into the global cardiology market
2. Access to highly regulated markets with necessary product approvals
3. Manufacturing footprint in Europe with FDA-approved facilities
4. Potential for significant synergies in manufacturing, R&D, and distribution

Synergies and Growth Prospects

Poly Medicure expects:

• EUR 3-4 million in incremental EBITDA synergies over the next 3-4 years
• PendraCare to reach EUR 25.00 million in revenue by 2030, driven by:
  • Deeper market penetration with existing products
  • Expansion into new markets leveraging Poly Medicure's distribution strength
  • Development and commercialization of new high-end products in neuro and structural heart segments

Operational Efficiency

PendraCare is consolidating operations:

• Moving from three locations to a single facility
• New facility details:
  • Total space: 2,300 square meters
  • Cleanroom area: 1,100 square meters
• Expected to improve operational efficiency without reducing production capacity

Future Outlook

This acquisition aligns with Poly Medicure's strategy to grow its cardiology business globally. The company plans to:

• Leverage PendraCare's existing distribution network
• Introduce its own products, including Drug Eluting Stents, in European and other international markets (pending regulatory approvals)

Himanshu Baid, Managing Director of Poly Medicure, stated, "This acquisition is a significant step in our global expansion strategy for the cardiology segment. We are excited about the potential synergies and the opportunity to bring innovative cardiology products to a wider market."

The remaining 10% stake in PendraCare, currently held by CEO Sander Hartman, is set to be acquired in 2030 based on the company's 2029 EBITDA performance.

As Poly Medicure integrates PendraCare into its operations, the medical device industry will be watching closely to see how this strategic move shapes the company's future in the global cardiology market.